Akums Drugs & Pharmaceuticals Ltd.
NSE: AKUMS
NSE
423.05
-7.40 (-1.72%)
Prev Close
430.45
Open Price
430.6
Volume
167,280
Today Low / High
419.95 / 432.45
52 WK Low / High
405 / 678.4
Range
402 - 444
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 423.05, with a change of -7.4 (-1.71913%). The expected target range on the NSE is between 402 - 444. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
12 Dec
430.60
-1.75%
11 Dec
423.05
1.77%
10 Dec
421.55
1.03%
09 Dec
417.75
0.91%
08 Dec
419.50
0.06%
05 Dec
417.85
0.39%
04 Dec
421.80
-0.36%
03 Dec
426.00
-1.14%
02 Dec
425.05
-0.07%
01 Dec
425.50
-0.34%
28 Nov
421.05
0.99%
27 Nov
426.60
-1.79%
26 Nov
420.05
1.48%
25 Nov
414.35
2.15%
24 Nov
423.75
-2.23%
21 Nov
420.75
0.21%
19 Nov
429.00
-1.04%
18 Nov
437.90
-1.69%
17 Nov
425.35
3.51%
Akums Drugs & Pharmaceuticals Ltd. Graph
Akums Drugs & Pharmaceuticals Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Akums Drugs & Pharmaceuticals Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 423.05, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 423.05 | 427.28 | 384.55 - 470.01 |
| 431.51 | 345.21 - 517.81 | ||
| 435.74 | 305.02 - 566.46 | ||
| Bearish Scenario | 423.05 | 418.82 | 376.94 - 460.70 |
| 414.59 | 331.67 - 497.51 | ||
| 410.36 | 287.25 - 533.47 |
Overview of Akums Drugs & Pharmaceuticals Ltd.
ISIN
INE09XN01023
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
169,515
Market Cap
64,769,825,637
Last Dividend
0
Official Website
IPO Date
2024-08-06
DCF Diff
432.55
DCF
-10
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,071.09 Cr | 2,465.74 Cr | 1,605.36 Cr | 0.3943 | 0.00 Cr | 47.21 Cr | 310.65 Cr | 338.18 Cr | 22.60 | 529.11 Cr | 0.0831 |
| 2024-03-31 | 4,019.68 Cr | 2,582.22 Cr | 1,437.46 Cr | 0.3576 | 0.00 Cr | 50.51 Cr | 359.90 Cr | -4.04 Cr | -0.28 | 130.61 Cr | -0.0010 |
| 2023-03-31 | 3,474.76 Cr | 2,307.47 Cr | 1,167.29 Cr | 0.3359 | 0.00 Cr | 52.12 Cr | 191.31 Cr | 94.86 Cr | 6.03 | 309.08 Cr | 0.0273 |
| 2022-03-31 | 3,646.83 Cr | 2,377.83 Cr | 1,269.00 Cr | 0.3480 | 0.00 Cr | 35.89 Cr | 322.21 Cr | -252.54 Cr | -16.04 | -82.18 Cr | -0.0692 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 101.19 Cr | 4,113.44 Cr | 1,049.83 Cr | 3,047.0140 Cr | 88.21 Cr | -12.98 Cr | 680.93 Cr | 1,563.65 Cr | 0.00 Cr | 13.68 Cr | 0.00 Cr | 893.7470 Cr |
| 2024-03-31 | 111.05 Cr | 3,516.37 Cr | 2,795.88 Cr | 709.4980 Cr | 565.23 Cr | 454.18 Cr | 630.43 Cr | 1,390.67 Cr | 0.00 Cr | 13.14 Cr | 0.00 Cr | 1,210.5520 Cr |
| 2023-03-31 | 51.61 Cr | 3,266.53 Cr | 2,543.15 Cr | 717.1890 Cr | 619.09 Cr | 567.49 Cr | 729.80 Cr | 1,212.31 Cr | 0.00 Cr | 15.19 Cr | 0.00 Cr | 1,265.5670 Cr |
| 2022-03-31 | 55.14 Cr | 3,069.05 Cr | 2,443.88 Cr | 621.9760 Cr | 394.98 Cr | 339.84 Cr | 722.45 Cr | 1,059.94 Cr | 0.00 Cr | 11.34 Cr | 0.00 Cr | 1,272.4180 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 465.1960 Cr | -547.8430 Cr | 72.7880 Cr | 192.8840 Cr | -9.8590 Cr | 101.1910 Cr | -272.3120 Cr | 345.2530 Cr | -477.9000 Cr | 0.0000 Cr | -50.5710 Cr |
| 2024-03-31 | 498.2590 Cr | -330.4150 Cr | -108.0210 Cr | 186.8510 Cr | 59.4420 Cr | 111.0500 Cr | -311.4080 Cr | -45.2780 Cr | -49.1910 Cr | 0.0000 Cr | 83.7290 Cr |
| 2023-03-31 | 176.6310 Cr | -304.7020 Cr | 124.5400 Cr | -152.1620 Cr | -3.5310 Cr | 51.6080 Cr | -328.7930 Cr | 150.2970 Cr | 177.9810 Cr | 0.0000 Cr | -7.3470 Cr |
| 2022-03-31 | 31.8540 Cr | -234.8220 Cr | 236.0400 Cr | -225.7280 Cr | 33.0720 Cr | 55.1390 Cr | -257.5820 Cr | -193.1970 Cr | 261.3230 Cr | 0.0000 Cr | -292.5890 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1,017.53 Cr | 592.56 Cr | 424.97 Cr | 0.4176 | 56.61 Cr | 40.78 Cr | 2.66 | 123.44 Cr | 0.0401 |
| 2025-06-30 | 1,024.03 Cr | 581.92 Cr | 442.12 Cr | 0.4317 | 92.05 Cr | 63.48 Cr | 4.15 | 150.83 Cr | 0.0620 |
| 2025-03-31 | 1,008.48 Cr | 671.39 Cr | 337.09 Cr | 0.3343 | 57.40 Cr | 147.62 Cr | 0.00 | 115.48 Cr | 0.1464 |
| 2024-12-31 | 1,010.41 Cr | 602.39 Cr | 408.02 Cr | 0.4038 | 76.85 Cr | 65.18 Cr | 4.26 | 140.71 Cr | 0.0645 |
| 2024-09-30 | 1,033.09 Cr | 595.95 Cr | 437.14 Cr | 0.4231 | 86.32 Cr | 65.21 Cr | 4.37 | 138.35 Cr | 0.0631 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 229.10 Cr | 1,448.72 Cr | 1,677.82 Cr | 746.23 Cr | 648.36 Cr | 3,293.49 Cr | 1,568.04 Cr | 5,159.29 Cr | 1,990.86 Cr |
| 2025-03-31 | 101.19 Cr | 480.76 Cr | 581.95 Cr | 778.05 Cr | 680.93 Cr | 2,274.61 Cr | 1,563.65 Cr | 4,113.44 Cr | 1,049.83 Cr |
| 2024-09-30 | 482.00 Cr | 342.29 Cr | 824.29 Cr | 949.31 Cr | 659.60 Cr | 2,623.60 Cr | 1,412.70 Cr | 4,270.40 Cr | 1,423.42 Cr |
| 2024-03-31 | 111.05 Cr | 176.77 Cr | 287.82 Cr | 833.81 Cr | 630.43 Cr | 1,940.88 Cr | 1,390.67 Cr | 3,516.37 Cr | 2,795.88 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,794.20 | ₹4,304,886,803,174.00 | ₹1,442,249.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,426.50 | ₹1,706,033,829,370.00 | ₹128,633.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,791.50 | ₹1,283,215,885,760.00 | ₹168,916.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,279.30 | ₹1,065,033,273,233.00 | ₹981,114.00 |
| Lupin Limited | LUPIN | ₹2,112.00 | ₹964,681,344,000.00 | ₹573,967.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹927.45 | ₹933,231,714,026.00 | ₹435,235.00 |
| Mankind Pharma Limited | MANKIND | ₹2,178.80 | ₹899,419,690,874.00 | ₹1,107,712.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,195.10 | ₹694,116,019,647.00 | ₹670,100.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,631.00 | ₹673,270,515,000.00 | ₹35,892.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,968.10 | ₹555,399,412,193.00 | ₹359,544.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,012.30 | ₹546,496,817,959.00 | ₹1,243,204.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,465.90 | ₹371,905,013,166.00 | ₹98,690.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,659.80 | ₹332,303,772,715.00 | ₹81,623.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,798.00 | ₹281,653,104,000.00 | ₹111,646.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,438.60 | ₹272,707,988,894.00 | ₹177,392.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,155.00 | ₹228,875,000,000.00 | ₹2,254.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,341.20 | ₹217,934,497,063.00 | ₹421,135.00 |
| Eris Lifesciences Limited | ERIS | ₹1,572.20 | ₹214,160,196,030.00 | ₹92,545.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,096.00 | ₹206,509,893,344.00 | ₹42,086.00 |
| Cohance Lifesciences Limited | COHANCE | ₹535.80 | ₹204,979,473,612.00 | ₹515,022.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹876.90 | ₹172,366,203,436.00 | ₹49,903.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,086.00 | ₹172,129,300,410.00 | ₹80,321.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹905.05 | ₹162,103,387,844.00 | ₹1,393,984.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,963.90 | ₹149,279,369,774.00 | ₹37,297.00 |
| Granules India Limited | GRANULES | ₹574.50 | ₹139,413,177,342.00 | ₹1,264,501.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹888.65 | ₹109,020,779,900.00 | ₹55,174.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,577.50 | ₹92,583,053,105.00 | ₹4,240.00 |
| Strides Pharma Science Limited | STAR | ₹882.55 | ₹81,347,028,741.00 | ₹94,112.00 |
| FDC Limited | FDC | ₹418.90 | ₹68,201,144,188.00 | ₹69,872.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹740.45 | ₹67,119,788,842.00 | ₹119,729.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹331.75 | ₹64,884,267,458.00 | ₹619,024.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹423.05 | ₹64,769,825,637.00 | ₹167,280.00 |
| Sequent Scientific Limited | SEQUENT | ₹209.68 | ₹52,383,058,368.00 | ₹957,574.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹137.08 | ₹44,485,419,283.00 | ₹1,212,051.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹849.95 | ₹43,108,703,295.00 | ₹33,260.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹390.00 | ₹42,496,453,350.00 | ₹58,924.00 |
| Innova Captab Limited | INNOVACAP | ₹721.40 | ₹41,282,063,781.00 | ₹31,617.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,316.40 | ₹38,310,974,346.00 | ₹5,767.00 |
| Suven Life Sciences Limited | SUVEN | ₹170.65 | ₹37,612,286,460.00 | ₹133,676.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹393.35 | ₹35,901,054,500.00 | ₹120,462.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹348.20 | ₹34,918,368,589.00 | ₹39,213.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹456.00 | ₹32,105,022,000.00 | ₹3,257.00 |
| Hikal Limited | HIKAL | ₹252.71 | ₹31,159,332,533.00 | ₹526,032.00 |
Key Executives
President of Human Resource
Mr. Arvind Srivastava
Gender: male
Year Born:
Corporate Quality Assurance Head
Mr. Shantanu R. Chobhe
Gender: male
Year Born:
General Manager of Strategy
Sahil Maheshwari
Gender: Not Specified
Year Born:
Company Secretary & Compliance Officer
Mr. Dharamvir Malik
Gender: male
Year Born:
President of Strategy, New Projects & Business Excellence
Mr. Sanjay Sharma
Gender: male
Year Born:
President of Operations & Whole Time Director
Mr. Sanjay Kumar Sinha
Gender: male
Year Born: 1958
Director of Corporate Growth & Excellence
Ms. Arushi Jain
Gender: female
Year Born:
Chief Financial Officer
Mr. Sumeet Sood
Gender: male
Year Born:
Co-Founder, MD & Whole Time Director
Mr. Sanjeev Jain
Gender: male
Year Born: 1966
Co Founder, MD & Director
Mr. Sandeep Jain
Gender: male
Year Born: 1967
FAQs about Akums Drugs & Pharmaceuticals Ltd.
Who is the CEO of the company?
The CEO is Sanjeev Jain.
What is the current market price of the stock?
The current price is ₹423.05.
What is the 52-week price range?
The range is ₹405-678.4.
What is the market capitalization of the company?
The market capitalization is ₹6,476.98 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 20.46.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Akums Drugs & Pharmaceuticals Ltd. (ISIN: INE09XN01023) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹6,476.98 crores and an average daily volume of 169,515 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.